Acadia Pharmaceuticals Stock Filter Stocks by Fundamentals
| ACAD Stock | USD 16.54 0.17 1.04% |
ACADIA Pharmaceuticals fundamentals help investors to digest information that contributes to ACADIA Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of ACADIA Stock. The fundamental analysis module provides a way to measure ACADIA Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to ACADIA Pharmaceuticals stock.
ACADIA | Shares Owned by Institutions |
ACADIA Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, ACADIA Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to ACADIA Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
ACADIA Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in ACADIA Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of ACADIA Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing ACADIA Pharmaceuticals' value.| Shares | Palo Alto Investors, Llc | 2024-09-30 | 2.5 M | First Trust Advisors L.p. | 2024-06-30 | 2.1 M | Tang Capital Management Llc | 2024-09-30 | 1.5 M | Norges Bank | 2024-06-30 | 1.5 M | Goldman Sachs Group Inc | 2024-06-30 | 1.3 M | Voloridge Investment Management, Llc | 2024-09-30 | 1.3 M | Man Group Plc | 2024-09-30 | 1.3 M | Charles Schwab Investment Management Inc | 2024-09-30 | 1.3 M | Connor Clark & Lunn Inv Mgmt Ltd | 2024-06-30 | 1.3 M | Baker Bros Advisors Lp | 2024-09-30 | 42.9 M | Vanguard Group Inc | 2024-09-30 | 13.8 M |
ACADIA Fundamentals
| Return On Equity | 0.27 | ||||
| Return On Asset | 0.0872 | ||||
| Profit Margin | 0.14 % | ||||
| Operating Margin | 0.13 % | ||||
| Current Valuation | 2.21 B | ||||
| Shares Outstanding | 166.39 M | ||||
| Shares Owned By Insiders | 0.54 % | ||||
| Shares Owned By Institutions | 97.10 % | ||||
| Number Of Shares Shorted | 9.53 M | ||||
| Price To Earning | (13.77) X | ||||
| Price To Book | 4.72 X | ||||
| Price To Sales | 2.93 X | ||||
| Revenue | 726.44 M | ||||
| Gross Profit | 145.49 M | ||||
| EBITDA | (67.83 M) | ||||
| Net Income | (61.29 M) | ||||
| Cash And Equivalents | 436.35 M | ||||
| Cash Per Share | 2.70 X | ||||
| Total Debt | 57.2 M | ||||
| Debt To Equity | 0.15 % | ||||
| Current Ratio | 4.53 X | ||||
| Book Value Per Share | 3.47 X | ||||
| Cash Flow From Operations | 16.7 M | ||||
| Short Ratio | 8.43 X | ||||
| Earnings Per Share | 0.78 X | ||||
| Price To Earnings To Growth | (0.42) X | ||||
| Target Price | 25.11 | ||||
| Number Of Employees | 620 | ||||
| Beta | 0.38 | ||||
| Market Capitalization | 2.72 B | ||||
| Total Asset | 748.96 M | ||||
| Retained Earnings | (2.43 B) | ||||
| Working Capital | 361.87 M | ||||
| Current Asset | 603.49 M | ||||
| Current Liabilities | 39.15 M | ||||
| Net Asset | 748.96 M |
About ACADIA Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze ACADIA Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ACADIA Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ACADIA Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether ACADIA Pharmaceuticals is a strong investment it is important to analyze ACADIA Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact ACADIA Pharmaceuticals' future performance. For an informed investment choice regarding ACADIA Stock, refer to the following important reports:Check out ACADIA Pharmaceuticals Piotroski F Score and ACADIA Pharmaceuticals Altman Z Score analysis. For information on how to trade ACADIA Stock refer to our How to Trade ACADIA Stock guide.You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ACADIA Pharmaceuticals. If investors know ACADIA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ACADIA Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 28.347 | Earnings Share 0.78 | Revenue Per Share 5.622 | Quarterly Revenue Growth 0.183 | Return On Assets 0.0872 |
The market value of ACADIA Pharmaceuticals is measured differently than its book value, which is the value of ACADIA that is recorded on the company's balance sheet. Investors also form their own opinion of ACADIA Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is ACADIA Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ACADIA Pharmaceuticals' market value can be influenced by many factors that don't directly affect ACADIA Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ACADIA Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if ACADIA Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ACADIA Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.